Claims

1. Use of a pharmaceutical composition in the manufacture of a medicament for prevention or therapy of glaucoma, increased intraocular pressure, and/or ocular hypertension, wherein

    - the pharmaceutical composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane selected from F6H8 and F4H5; and

    - the pharmaceutical composition is to be administered to the eye of a subject; and

    - the amount of latanoprost is to be administered in a single dose per eye is in the range of from about 1.0 to 1.2 µg; and

    - the pharmaceutical composition is to be administered once daily.

2. The use according to claim 1 wherein the semifluorinated alkane is F6H8.

3. The use according to claim 1 or 2, wherein the pharmaceutical composition is to be administered topically to the eye of a subject.

4. The use according to any one of the preceding claims, wherein the single dose of the pharmaceutical composition is to be administered as one single drop to an eye of a subject.

5. The use according to any one of the preceding claims, wherein the pharmaceutical composition further comprises a solubilising agent.

6. The use according to claim 5, wherein solubilising agent is selected from ethanol, medium chain triglycerides (MCT) and diethylene glycol monoethyl ether (DEGEE).

7. The use according to claim 5 or 6, wherein the solubilising agent is comprised in an amount of up to 2.5 % (w/w) with respect to the total weight of the liquid vehicle.

8. The use according to any one of claims 5 to 7, wherein the solubilising agent is ethanol.

9. The use according to any one of the preceding claims, wherein the pharmaceutical composition is substantially free of water and of a preservative.

10. The use according to any one of the preceding claims, wherein the pharmaceutical composition target dose volume per eye is from about 8 to 15 µl, preferably from about 10 to 12 µl.

11. The use according to any one of the preceding claims, wherein the pharmaceutical composition comprises about 0.005 to 0.015 % (w/v), preferably about 0.008 to 0.012 % (w/v) latanoprost.

12. The use according to any one of the preceding claims, wherein the pharmaceutical composition comprises about 0.01% (w/v) latanoprost, and wherein the latanoprost is to be administered in a single dose per eye is about 1.1 µg and wherein the pharmaceutical composition target dose volume per eye is about 11 µl.

13. The use according to any one of the preceding claims, wherein the pharmaceutical composition comprises latanoprost dissolved in a liquid vehicle essentially consisting of at least 99 % (w/w) of 1-perfluorobutyl-pentane ($CF_3(CF_2)_3$-$(CH_2)_4CH_3$ (F4H5)) or 1-perfluorohexyl-octane ($CF_3(CF_2)_5$-$(CH_2)_7CH_3$ (F6H8)) and up to 1 % (w/w) ethanol, with respect to the total weight of the liquid vehicle.

14. The use according to any one of the preceding claims, wherein the pharmaceutical composition is to be administered once daily.

15. A kit comprising the pharmaceutical composition according to any one of the preceding claims, wherein the kit comprises a container for holding the pharmaceutical composition and a drop dispenser for administering the pharmaceutical composition.